The CMS' plan to eliminate Medicare payments for new off-campus outpatient departments has kicked up fierce opposition from hospitals. As the comment period comes to a close, hospitals argue it threatens not just lost revenue but also substantial and unavoidable legal risks.

Cal INDEX, a highly touted database of patient medical records backed by two of California’s largest health insurers, is searching for a new chief executive as it tries to overcome a slow start.

Following weeks of criticism over dramatic price increases on its EpiPen, Mylan said Monday it will offer a generic version of the life-saving allergy treatment.

At least eight pharmaceutical companies sell a decades-old drug that treats gallstones, but the competition has done little to keep its price down.

State Sen. Ed Hernandez's attempt to push through a drug pricing transparency bill sputtered this year, but the West Covina Democrat still wants his colleagues to weigh in on the latest controversy in the cost of prescription drugs: the surging price of EpiPens.

This year, taxpayers will cover about 70 percent of what is spent on health care in California, according to a new analysis released Wednesday by the UCLA Center for Health Policy Research.